Contribution of protein kinase Cα in the stimulation of insulin by the down-regulation of Cavβ subunits

Ion channels regulate energy homeostasis and the progression of metabolic disorders: Novel mechanisms and pharmacology of their modulators

The progression of metabolic diseases, featured by dysregulated metabolic signaling pathways, is orchestrated by numerous signaling networks. Among the regulators, ion channels transport ions across the membranes and trigger downstream signaling transduction. They critically regulate energy homeostasis and pathogenesis of metabolic diseases and are potential therapeutic targets for treating metabolic disorders. Ion channel blockers have been used to treat diabetes for decades by stimulating insulin secretion, yet with hypoglycemia and other adverse effects. It calls for deeper understanding of the largely elusive regulatory mechanisms, which facilitates the identification of new therapeutic targets and safe drugs against ion channels. In the article, we critically assess the two principal regulatory mechanisms, protein-channel interaction and post-translational modification on the activities of ion channels to modulate energy homeostasis and metabolic disorders through multiple novel mechanisms. Moreover, we discuss the multidisciplinary methods that provide the tools for elucidation of the regulatory mechanisms mediating metabolic disorders by ion channels. In terms of translational perspective, the mechanistic analysis of recently validated ion channels that regulate insulin resistance, body weight control, and adverse effects of current ion channel antagonists are discussed in details. Their small molecule modulators serve as promising new drug candidates to combat metabolic disorders.

Eugenol Improves Insulin Secretion and Content of Pancreatic Islets from Male Mouse

Glucose homeostasis is required for control of insulin secretion. Phenolic compounds improved glucose-stimulated insulin secretion (GSIS). Eugenol is a phenolic compound that may increase GSIS. So, it was decided to investigate the effect of eugenol on the insulin secretion and content of pancreatic islets from the male mice. In this experimental study, 3-month-old NMRI mice (20-25 g) were prepared. The pancreatic islets of Langerhans were isolated using the collagenase digestion method and divided into 12 groups: glucose 2.8, 5.6, and 16.7 mM, glucose 2.8 mM + eugenol 50, 100, and 200 µM, glucose 5.6 mM + eugenol 50, 100, and 200 µM, and glucose 16.7 mM + eugenol 50, 100, and 200 µM. The islet's insulin secretion and content were measured after 1 hour and 24 hours incubation at 37°C, respectively, by the ELISA assays method and related commercial kit. Present results showed that all doses of eugenol increased islet's insulin secretion and content in the medium containing glucose concentrations 2.8, 5.6, and 16.7 mM (P < 0.05). In conclusion, eugenol as a phenolic compound increased insulin secretion and content of pancreatic islets. The moderate dose of this compound enhanced insulin secretion during hypo- and hyperglycemic conditions, as well as a high dose of eugenol, increased insulin content. Finally, present research suggested that the administration of eugenol 100 µM was suitable for the early stage of T2DM as well as eugenol 200 µM for the advanced stage of this disease.

Protein partners of the calcium channel β subunit highlight new cellular functions

Calcium plays a key role in cell signalling by its intervention in a wide range of physiological processes. Its entry into cells occurs mainly via voltage-gated calcium channels (VGCC), which are found not only in the plasma membrane of excitable cells but also in cells insensitive to electrical signals. VGCC are composed of different subunits, α1, β, α2δ and γ, among which the cytosolic β subunit (Cavβ) controls the trafficking of the channel to the plasma membrane, its regulation and its gating properties. For many years, these were the main functions associated with Cavβ. However, a growing number of proteins have been found to interact with Cavβ, emphasizing the multifunctional role of this versatile protein. Interestingly, some of the newly assigned functions of Cavβ are independent of its role in the regulation of VGCC, and thus further increase its functional roles. Based on the identity of Cavβ protein partners, this review emphasizes the diverse cellular functions of Cavβ and summarizes both past findings as well as recent progress in the understanding of VGCC.

Acute effect of 3β-hidroxihop-22(29)ene on insulin secretion is mediated by GLP-1, potassium and calcium channels for the glucose homeostasis

The effect of 3β-hidroxihop-22(29)ene (3-BHO) on insulin and glucagon-like peptide 1 (GLP-1) secretion as well as the mechanism of action of the compound in pancreatic islet on glucose homeostasis was investigated. The data from in vivo treatment show that 3-BHO significantly reduces the hyperglycemia by increasing the insulin and GLP-1 secretion, as well as by accumulating hepatic glycogen in hyperglycemic rats. In rat pancreatic β-cell, 3-BHO stimulates the glucose uptake, insulin vesicles translocation to the plasma membrane and thus the insulin secretion through the involvement of potassium channels (ATP- and Ca(2+)-dependent K(+) channels) and calcium channels (L-type voltage-dependent calcium channels (L-VDCC)). Furthermore, this study also provides evidence for a crosstalk between intracellular high calcium concentration, PKA and PKC in the signal transduction of 3-BHO to stimulate insulin secretion. In conclusion, 3-BHO diminishes glycaemia, stimulates GLP-1 secretion and potentiates insulin secretion and increase hepatic glycogen content. Moreover, this triterpene modulates calcium influx characterizing ATP-K(+), Ca(2+)-K(+) and L-VDCC channels-dependent pathways as well as PKA and PKC activity in pancreatic islets underlying the signaling of 3-BHO for the secretory activity and contribution on glucose homeostasis.